2022
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study
Beshir K, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K, Ceesay S, Bazie T, Kolie F, Lamine M, Cairns M, Snell P, Scott S, Diallo A, Merle C, NDiaye J, Razafindralambo L, Moroso D, Ouedraogo J, Zongo I, Kessely H, Doumagoum D, Bojang K, Ceesay S, Loua K, Maiga H, Dicko A, Sagara I, Laminou I, Ogboi S, Eloike T, Milligan P, Sutherland C. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. The Lancet Infectious Diseases 2022, 23: 361-370. PMID: 36328000, DOI: 10.1016/s1473-3099(22)00593-x.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionResistance-associated variantsParasite carriageSurvey-weighted prevalenceMalaria transmission seasonQuantitative PCRPrevalence ratiosP falciparumGenomic surveillance studyChemoprevention drugsBlood samplesSurveillance studyTransmission seasonChemopreventionPlasmodium falciparumAmodiaquinePrevalenceMDR1Variant haplotypeSequencing of isolatesSignificant reductionChildrenPyrimethamineCommunity survey
2021
Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries
Cairns M, Ceesay S, Sagara I, Zongo I, Kessely H, Gamougam K, Diallo A, Ogboi J, Moroso D, Van Hulle S, Eloike T, Snell P, Scott S, Merle C, Bojang K, Ouedraogo J, Dicko A, Ndiaye J, Milligan P. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. PLOS Medicine 2021, 18: e1003727. PMID: 34495978, PMCID: PMC8457484, DOI: 10.1371/journal.pmed.1003727.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, WesternAge FactorsAmodiaquineAntimalarialsCase-Control StudiesChild, PreschoolCommunicable Disease ControlDrug CombinationsFemaleHumansIncidenceInfantMalaria, FalciparumMaleParasite LoadPlasmodium falciparumProgram EvaluationPyrimethamineRisk AssessmentRisk FactorsSeasonsSulfadoxineTime FactorsTreatment OutcomeConceptsSeasonal malaria chemopreventionCase-control studyClinical malariaOdds ratioClinical trialsNational Malaria Control ProgrammeClinical malaria incidenceIndividual case-control studiesIncidence rate ratiosHigh protective efficacyConditional logistic regressionMalaria control activitiesMalaria control programmesPersonal protectionCase-control designChemoprevention treatmentMalaria chemopreventionSevere malariaSMC treatmentMean agePrimary exposureProtective efficacyResidual confoundingHealth facilitiesParasite densitySeasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga R, Diarra M, Nikièma F, Tapily A, Sompougdou F, Issiaka D, Zoungrana C, Sanogo K, Haro A, Kaya M, Sienou A, Traore S, Mahamar A, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Ouédraogo J, Dicko A, Greenwood B. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. New England Journal Of Medicine 2021, 385: 1005-1017. PMID: 34432975, DOI: 10.1056/nejmoa2026330.Peer-Reviewed Original ResearchConceptsUncomplicated malariaProtective efficacyClinical malariaSevere malariaMalaria-related outcomesSeasonal malaria chemopreventionUncomplicated clinical malariaVaccine-alone groupWorld Health Organization definitionPrespecified noninferiority marginMonths of ageMalaria chemopreventionSeasonal vaccinationFirst doseHazard ratioMalaria vaccinationFebrile seizuresHospital admissionCombination groupNoninferiority marginLower incidenceAS01ChemopreventionChildren 5Organization definitionEffect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness
Yaméogo K, Yerbanga R, Ouattara S, Yao F, Lefèvre T, Zongo I, Nikièma F, Compaoré Y, Tinto H, Chandramohan D, Greenwood B, Belem A, Cohuet A, Ouédraogo J. Effect of seasonal malaria chemoprevention plus azithromycin on Plasmodium falciparum transmission: gametocyte infectivity and mosquito fitness. Malaria Journal 2021, 20: 326. PMID: 34315475, PMCID: PMC8314489, DOI: 10.1186/s12936-021-03855-3.Peer-Reviewed Original ResearchConceptsAddition of azithromycinMalaria chemopreventionSulfadoxine-pyrimethamineGametocyte infectivityAsexual Plasmodium falciparumDirect membrane feeding assaysSeasonal malaria chemopreventionPlacebo-controlled trialPlasmodium falciparum transmissionMembrane feeding assaysInfectivity of gametocytesControl of malariaPresence of malariaMalaria transmission periodDays post treatmentAnopheles gambiae mosquitoesGametocyte prevalenceMethodsThe studyConclusionThis studyMalaria transmissionP. falciparumControl childrenMosquito transmissionAppropriate interventionsChemoprevention
2020
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study
Partnership A, Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, Roca-Feltrer A, Sanogo A, Johansson J, Tibenderana J, Abdoulaye R, Coulibaly P, Hubbard E, Jah H, Lama E, Razafindralambo L, Van Hulle S, Jagoe G, Tchouatieu A, Collins D, Gilmartin C, Tetteh G, Djibo Y, Ndiaye F, Kalleh M, Kandeh B, Audu B, Ntadom G, Kiba A, Savodogo Y, Boulotigam K, Sougoudi D, Guilavogui T, Keita M, Kone D, Jackou H, Ouba I, Ouedraogo E, Messan H, Jah F, Kaira M, Sano M, Traore M, Ngarnaye N, Elagbaje A, Halleux C, Merle C, Iessa N, Pal S, Sefiani H, Souleymani R, Laminou I, Doumagoum D, Kesseley H, Coldiron M, Grais R, Kana M, Ouedraogo J, Zongo I, Eloike T, Ogboi S, Achan J, Bojang K, Ceesay S, Dicko A, Djimde A, Sagara I, Diallo A, NdDiaye J, Loua K, Beshir K, Cairns M, Fernandez Y, Lal S, Mansukhani R, Muwanguzi J, Scott S, Snell P, Sutherland C, Tuta R, Milligan P. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. The Lancet 2020, 396: 1829-1840. PMID: 33278936, PMCID: PMC7718580, DOI: 10.1016/s0140-6736(20)32227-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAfrica, CentralAfrica, WesternAmodiaquineAntimalarialsCase-Control StudiesChemopreventionChildCost-Benefit AnalysisDrug CombinationsDrug ResistanceFeasibility StudiesHumansIncidenceMalariaProgram EvaluationPyrimethamineSafetySeasonsSulfadoxineSurveys and QuestionnairesYoung AdultConceptsSeasonal malaria chemopreventionCase-control studyHigh transmission periodMalaria chemopreventionObservational studyHealth-care staff timeHigh malaria transmission seasonDrug resistanceSerious adverse drug reactionsMalaria transmission seasonSerious adverse reactionsSevere skin reactionsCommunity health workersNational health management information systemAdverse drug reactionsCost-effectiveness ratioHealth Management Information SystemIndividual case safetyTarget populationMarker of resistanceSMC treatmentHospital admissionOutpatient clinicDrug reactionsSkin reactionsSerotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin
Hema-Ouangraoua S, Zongo I, Kabore N, Frédéric N, Yerbanga R, Tinto H, Compaore Y, Kuepfer I, Chandramohan D, Greenwood B, Ouedraogo J. Serotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin. American Journal Of Tropical Medicine And Hygiene 2020, 103: 679-683. PMID: 32524945, PMCID: PMC7410481, DOI: 10.4269/ajtmh.19-0944.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnti-Bacterial AgentsAntimalarialsAzithromycinBurkina FasoCarrier StateChemopreventionChild, PreschoolDrug CombinationsDrug Resistance, BacterialDrug Therapy, CombinationFemaleHumansInfantMalariaMaleMass Drug AdministrationNasopharynxPneumococcal InfectionsPneumococcal VaccinesPyrimethamineSeasonsSerogroupStreptococcus pneumoniaeSulfadoxineConceptsSeasonal malaria chemopreventionMass drug administrationEmergence of resistancePneumococcal serotypesDrug AdministrationStreptococcus pneumoniaeDistribution of serotypesMalaria chemopreventionNasopharyngeal isolatesMass administrationCarriage studiesAzithromycinQuellung techniqueSwift appearanceSpecific serotypesSingle serotypeAdministrationAntibiotic resistanceSerotype profileSerotypesDifferent serotypesMultiplex assayPneumoniaePCR techniqueIsolates
2019
Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention
Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, Diarra M, Barry A, Tapily A, Nikiema F, Yerbanga S, Coumare S, Thera I, Traore A, Milligan P, Tinto H, Doumbo O, Ouedraogo J, Greenwood B. Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. New England Journal Of Medicine 2019, 380: 2197-2206. PMID: 30699301, DOI: 10.1056/nejmoa1811400.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnti-Bacterial AgentsAntimalarialsAzithromycinBurkina FasoChild MortalityChild, PreschoolDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationFemaleHospitalizationHumansIncidenceInfantInfant MortalityMalariaMaleMaliMass Drug AdministrationParasitemiaPyrimethamineSulfadoxineConceptsSeasonal malaria chemopreventionAddition of azithromycinMalaria transmission seasonMalaria chemopreventionHospital admissionAnnual malaria transmission seasonsUpper respiratory tract infectionNonmalarial febrile illnessesPrimary end pointRespiratory tract infectionsAntimalarial agentsLow disease burdenYears of ageMonths of ageAzithromycin groupCause mortalityPlacebo groupAdverse eventsFebrile illnessMalaria parasitemiaTract infectionsTreat analysisElective surgeryDisease burdenGastrointestinal infections
2015
Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine
Tahita M, Tinto H, Erhart A, Kazienga A, Fitzhenry R, VanOvermeir C, Rosanas-Urgell A, Ouedraogo J, Guiguemde R, Van geertruyden J, D’Alessandro U. Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. PLOS ONE 2015, 10: e0137440. PMID: 26368675, PMCID: PMC4569438, DOI: 10.1371/journal.pone.0137440.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntimalarialsBurkina FasoDihydropteroate SynthaseDrug CombinationsDrug ResistanceFemaleHumansMalaria, FalciparumMutationPlasmodium falciparumPregnancyPregnancy Trimester, SecondPregnancy Trimester, ThirdPrevalenceProtozoan ProteinsPyrimethamineSulfadoxineTetrahydrofolate DehydrogenaseYoung AdultConceptsIntermittent preventive treatmentPregnant womenPfdhps genesPreventive treatmentAntenatal careSulfadoxine-pyrimethamineThird trimesterDhps mutationsPfdhfr mutationsMalaria infectionMalaria symptomsHealth districtPfdhfr geneBlood samplesSP resistanceI164L mutationEndemic regionsReductase mutationMalaria controlDrug resistancePrevalenceAdverse effectsFive yearsWomenBurkina FasoRandomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso
Zongo I, Milligan P, Compaore Y, Some A, Greenwood B, Tarning J, Rosenthal P, Sutherland C, Nosten F, Ouedraogo J. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2015, 59: 4387-4396. PMID: 25918149, PMCID: PMC4505196, DOI: 10.1128/aac.04923-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionAlternative drugsControl groupPrimary outcome measureSeasonal malaria transmissionRandomized noninferiority trialPotential alternative drugDihydroartemisinin-PiperaquinePfdhps mutationsClinical malariaMalaria attacksSulfadoxine-pyrimethamineOdds ratioNoninferiority trialOutcome measuresDHAPQChildren 3Malaria transmissionDrug resistanceAntifolate resistanceChemopreventionChildrenAmodiaquineTrials
2012
An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso
Valea I, Tinto H, Drabo M, Huybregts L, Sorgho H, Ouedraogo J, Guiguemde R, van Geertruyden J, Kolsteren P, D'Alessandro U, the FSP/MISAME study Group. An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malaria Journal 2012, 11: 71. PMID: 22433778, PMCID: PMC3338396, DOI: 10.1186/1475-2875-11-71.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemiaAntimalarialsBurkina FasoDrug Administration ScheduleDrug CombinationsFemaleHumansInfant, Low Birth WeightInfant, NewbornMalaria, FalciparumPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPregnancy TrimestersProspective StudiesPyrimethamineRiskSulfadoxineTime FactorsYoung AdultConceptsLow birth weightFirst malaria infectionDoses of SPMalaria infectionBirth weightPerinatal mortalityMaternal anemiaFirst trimesterPregnant womenHigh riskBackgroundA prospective studyIntermittent preventive treatmentAntenatal care visitsHistory of feverIncidence rate ratiosCare visitsThird doseMethodsStudy participantsProspective studySecond trimesterPreventive treatmentHealth centersHealth facilitiesPregnancyInsecticidal nets
2010
Selection of Known Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperaquine in Burkina Faso
Somé A, Séré Y, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouédraogo J, Rosenthal P. Selection of Known Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperaquine in Burkina Faso. Antimicrobial Agents And Chemotherapy 2010, 54: 1949-1954. PMID: 20231394, PMCID: PMC2863637, DOI: 10.1128/aac.01413-09.Peer-Reviewed Original ResearchAmodiaquineAntimalarialsArtemetherArtemisininsBurkina FasoDrug CombinationsDrug Resistance, BacterialEthanolaminesFluorenesGenotypeHumansInfantLumefantrineMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsPyrimethamineQuinolinesRandomized Controlled Trials as TopicRecurrenceSulfadoxine
2007
Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal P, Ouédraogo J. Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Diseases 2007, 45: 1453-1461. PMID: 17990228, DOI: 10.1086/522985.Peer-Reviewed Original ResearchConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum malariaFalciparum malariaArtemether-lumefantrineRecurrent parasitemiaUncomplicated P. falciparum malariaCombination antimalarial therapyEarly treatment failureSerious adverse eventsP. falciparum malariaDrug-resistant parasitesYears of ageMonths of ageAntimalarial regimenDihydroartemisinin-PiperaquineLumefantrine regimenAdverse eventsCombination regimensSulfadoxine-pyrimethamineRandomized comparisonTreatment failureNew regimenRecurrent malariaAntimalarial therapyTreatment groupsSulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Tinto H, Ouédraogo J, Zongo I, van Overmeir C, van Marck E, Guiguemdé T, D'Alessandro U. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. American Journal Of Tropical Medicine And Hygiene 2007, 76: 608-13. PMID: 17426157, DOI: 10.4269/ajtmh.2007.76.608.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnimalsAntimalarialsBurkina FasoChildChild, PreschoolChloroquineDrug Administration ScheduleDrug CombinationsDrug ResistanceFemaleGenotypeHumansInfantMalaria, FalciparumMaleMutationPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPyrimethamineSelection, GeneticSulfadoxineTetrahydrofolate DehydrogenaseConceptsSulfadoxine-pyrimethamine efficacyTriple dhfr mutationDHFR mutationsRecurrent parasitemiaIntermittent preventive treatmentSulfadoxine-pyrimethamine resistanceYears of ageSuch high prevalenceDihydropteroate synthetase (Pfdhps) mutationsPCR-restriction fragment length polymorphismSulfadoxine-pyrimethamineTreatment failurePregnant womenPolymerase chain reactionPreventive treatmentHigh prevalenceNew infectionsChain reactionMutant parasitesPatientsParasitemiaTreatmentFragment length polymorphismPrevalenceEfficacyArtemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde R, Rosenthal P, Ouedraogo J. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. The Lancet 2007, 369: 491-498. PMID: 17292769, DOI: 10.1016/s0140-6736(07)60236-0.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaTreatment failureUncomplicated malariaArtemether-lumefantrineRecurrent parasitaemiaFalciparum malariaNew infectionsArtemisinin-based combination treatmentLate treatment failureEarly treatment failureNon-inferiority trialSymptomatic malariaEffective regimensPrimary endpointCombination regimensStandard dosesAvailable regimenCombination treatmentDrug susceptibilityPatientsAmodiaquineMalarial treatmentMalariaRegimensBobo-Dioulasso
2006
In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs.
Tinto H, Sanou B, Erhart A, D'Alessandro U, Ouédraogo J, Guiguemdé T. In vivo sensitivity of Plasmodium faciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs. Bulletin De La Société De Pathologie Exotique 2006, 99: 161-5. PMID: 16983817.Peer-Reviewed Original ResearchConceptsCQ treatment failureTreatment failureRisk factorsMultivariate analysisVivo field testTotal treatment failureYears of ageTime of recruitmentSignificant increaseSulfadoxine-pyrimethamineCQ groupUnivariate analysisHealth centersAge of childrenLate failureLow parasitaemiaBetter efficacyDay 14Therapeutic efficacyDay 0SP groupVivo sensitivityParasitaemiaChloroquineDrugsRoles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso.
Dokomajilar C, Lankoande Z, Dorsey G, Zongo I, Ouedraogo J, Rosenthal P. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2006, 75: 162-5. PMID: 16837725, DOI: 10.4269/ajtmh.2006.75.162.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnimalsAntimalarialsBurkina FasoDihydropteroate SynthaseDrug CombinationsDrug ResistanceGenes, MDRHumansMembrane ProteinsMembrane Transport ProteinsMutationPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsPyrimethamineRecurrenceSulfadoxineTetrahydrofolate DehydrogenaseConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum mutationsPlasmodium falciparum malariaP. falciparum resistanceFalciparum malariaFalciparum resistanceNew infectionsAmodiaquineDhfr-164LBobo-DioulassoSignificant increaseBurkina FasoSame mutationTreatmentKey polymorphismsMutationsTarget genesTherapyInfectionMalariaPrevalenceRecrudescence
2005
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo J, Rosenthal P. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2005, 73: 826-32. PMID: 16282288, DOI: 10.4269/ajtmh.2005.73.826.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaFalciparum malariaTreatment failureEfficacy of amodiaquineEarly treatment failureSerious adverse eventsPatients 6 monthsRisk of recrudescenceEfficacy outcomesUncomplicated malariaAdverse eventsWHO criteriaAvailable therapiesCombination therapyAntimalarial therapyClinical failureNew infectionsAmodiaquineBurkina FasoTherapyRelative efficacyMalariaBobo-DioulassoPyrimethamineTrials
2003
Malaria: use of restriction endonuclease digestion and mutation-specific PCR for antifolate resistance isolate detection.
Kengne P, Ouédraogo J, Zampan H, Veas F, Guiguemdé T. Malaria: use of restriction endonuclease digestion and mutation-specific PCR for antifolate resistance isolate detection. Parassitologia 2003, 45: 27-31. PMID: 15270541.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAnimalsAntimalarialsDNA Mutational AnalysisDNA, ProtozoanDrug ResistanceFolic Acid AntagonistsHumansMalaria, FalciparumMutation, MissenseParasitemiaPlasmodium falciparumPoint MutationPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthProguanilProtozoan ProteinsPyrimethamineTetrahydrofolate DehydrogenaseConceptsMutation-specific PCRCycloguanil resistanceBlood samplesResistance isolatesResistance mutationsPlasmodium falciparumMixed infectionsChemosensitivity analysisBloodWhole bloodParasite lysateRapid DNA extractionPCR productsRestriction endonuclease digestionPCRAmplified productsDry filter paperPCR technologyPoint mutationsEndonuclease digestionUndigested samplesPatientsInfectionPyrimethamineMutations
2002
Chloroquine and sulphadoxine‐pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo‐Dioulasso, Burkina Faso during a 3‐year period 1998–2000
Tinto H, Zoungrana E, Coulibaly S, Ouedraogo J, Traoré M, Guiguemde T, Van Marck E, D'Alessandro U. Chloroquine and sulphadoxine‐pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo‐Dioulasso, Burkina Faso during a 3‐year period 1998–2000. Tropical Medicine And International Health 2002, 7: 925-930. PMID: 12390597, DOI: 10.1046/j.1365-3156.2002.00952.x.Peer-Reviewed Original ResearchConceptsPrevalence of anemiaClinical failureParasitological resistancePacked cell volumeUncomplicated malariaDay 14Day 0Uncomplicated malaria treatmentHaematological recoveryMalaria treatmentCQ resistanceHealth centersRegular surveillanceAntimalarial drugsChloroquineBurkina FasoPrevalenceBobo-DioulassoChildrenAnemiaEvidence of increasesMalariaTreatmentFailureCell volume
1996
How to perform and interpret the results of a chemoresistance test of Plasmodium falciparum in malaria patients in a tropical region.
Guiguemdé R, Gbary R, Coulibaly S, Ouedraogo J. How to perform and interpret the results of a chemoresistance test of Plasmodium falciparum in malaria patients in a tropical region. Cahiers De Santé 1996, 6: 187-91. PMID: 8764454.Peer-Reviewed Original Research